Additional info she sent...
The FAHF-2 study will include approximately 68 patients (about 20 from Chicago), and is a multi-center study being conducted at Mount Sinai in New York, Arkansas Children's Hospital Research Institute in Little Rock, and Lurie Children's here in Chicago. The study is being funded by NIH/National Center for Complementary and Alternative Medicine and Food Allergy Initiative.
Safety:
In the earlier phase clinical trial of FAHF-2 some participants have had abdominal complaints like pain, constipation, nausea, or fullness, most of which have been short-lived and appear to respond to taking the pills with meals. Trained Children's Memorial Hospital nurses and research staff will be present during all study visits, and a doctor will be on call in case of emergency. Participants will also have access to the study physician at Children's Memorial Hospital to discuss adverse events by phone, and participants can call study coordinator and physician on call during off hours.
Study Procedures:
* An initial evaluation that includes: medical history; physical exam; skin prick testing to the chosen allergen (peanuts, individual tree nuts, sesame, and/or individual fish or shellfish); blood draw; pulmonary function test (a breathing test); electrocardiogram (EKG); urinalysis; and a pregnancy test for girls (as needed). We do all of this in order to get baseline data so we have something to compare to at the end of the study.
* A two day double-blind placebo-controlled food challenge, where we do a food challenge with a placebo on one day and a challenge with the allergen chosen for the study on the other day.
* For the duration of the study, participants will take 10 pills (either FAHF-2 or placebo) 3 times daily for 6 months, complete a symptom diary, and talk to the research staff by telephone each week for the first 4 weeks, then every 2 weeks until the end of the treatment.
* Participants will attend a study visit every 2 months (these visits will include a physical, a blood sample, a pulmonary function test, urinalysis, and routine blood tests).
* At the end of the 6 months of treatment, there will be another study visit which repeats most of the tests done at the initial evaluation including blood tests, pulmonary function test, and skin prick test. By performing these tests after completing treatment, we can evaluate the effectiveness of the drug on the food allergen selected by comparing these results to the original baseline results from the first visit.
* A two day double-blind placebo-controlled food challenge, where we do a food challenge with a placebo on one day and a challenge with the allergen chosen for the study on the other day.
* For those participants who demonstrate an improvement in tolerance, a repeat food challenge will be performed 3 months after the end of the therapy to evaluate the duration of the effect.
Leslie Lesner
Community Outreach Coordinator, Davison of Allergy & Immunology
Ann & Robert H. Lurie Children's Hospital of Chicago
T 312.227.6458 | F 312.227.9401 | llesner@luriechildrens.org | luriechildrens.org
225 East Chicago Avenue, Box 60, Chicago, Illinois 60611-2605
Facebook | Twitter | YouTube